Bausch Health (BHC) Q3 2026 earnings review
Bausch Health raises its 2026 outlook, but aesthetics sales shrink
Bausch Health, the maker of Xifaxan gut medication and Thermage skin devices, beat its second-half pace even as its aesthetics unit lost momentum. Sales from businesses owned a year ago rose 8%, while operating cash flow doubled to $813 million and trimmed net debt. Chief executive Thomas J. Appio raised the full-year outlook across every measure, though by our math the core plan still points to an 8.6% sales drop in the fourth quarter.
| Sales from businesses owned a year ago | +8% reported revenue $2.94B (+10% from a year ago) |
|---|---|
| Profit per share, excluding one-offs | $1.77 +53% from a year ago |
| Ebitda excluding one-offs and Bausch + Lomb | $1,022M +32% from a year ago |
| Full-year revenue outlook (excl. B+L) | Raised $150M middle of the range: $5.58B (+8% growth) |
⚖️ Verdict: 🟢 Bullish
The story got better because the core drug business kept growing even after lapping last year's exit from high-rebate government channels, funding another $200 million increase to the cash flow plan. One caution: underlying sales at the Solta aesthetics unit fell 4% as Asia Pacific weakened, hurting the main business expected to offset upcoming Xifaxan patent expirations.
The question now is whether third-quarter cash and profit gains carry into 2027 or vanish when Medicare price cuts for Xifaxan begin in January. Either underlying prescription demand is strengthening enough to lift the $2.7 billion 2027 Ebitda target, or this year's beats are temporary pricing gains before a steep reset. Management's 2027 commentary on the call and fourth-quarter results will settle it.
🐂 Bull Case
Raised 2026 Plan Still Points to a Q4 Drop
Bausch Health's core business — which excludes its Bausch + Lomb eye-care subsidiary — beat the pace implied by its prior full-year plan. "These results give us confidence to again raise our full year 2026 guidance," chief executive Thomas J. Appio said. Core sales reached $1.57 billion, up 12% as reported and up 8% from businesses owned a year ago, led by the Salix gut-health unit.
- Salix sales: $831 million, up 16% as reported and 14% from businesses owned a year ago
- Xifaxan, its main gut-infection drug: revenue up 16% from a year ago
- Core full-year revenue outlook: raised by $150 million at the middle of the range to $5.58 billion
- Implied fourth-quarter core revenue: $1.27 billion, down 8.6% from a year ago by our math
The third-quarter beat shows that the Q2 plan was cautious, because Salix grew 14% on an underlying basis even while lapping last year's exit from high-rebate government channels. However, the higher full-year outlook still points to an 8.6% sales drop in the fourth quarter by our math, because expected Medicare rebate charges and generic competition for the antidepressant Aplenzin sit in the final months of the year.
What to watch: fourth-quarter core revenue against the implied $1.27 billion mark. A figure near $1.4 billion would show that underlying demand in Salix is absorbing the year-end rebate charges better than the company's plan assumes.
Lower Production and Research Costs Lifted Margins
Profitability expanded across the pharmaceutical group as both production costs and one-time research charges fell. Appio noted that quarterly Ebitda excluding one-offs and Bausch + Lomb reached $1.02 billion, "exceeding $1 billion for the first time". That figure rose 32% from a year ago, while total operating income rose by $364 million to $983 million, lifting the operating margin by 10.3 percentage points to 33.4%.
Three expense lines drove the margin increase. Cost of goods sold — the direct cost of making the products — fell by 2.9 percentage points of revenue to 24.5%, while selling and overhead costs dropped 1.3 points to 28.4%. Other operating expenses fell by 2.7 points because last year's third quarter included an $81 million upfront research charge from buying Durect; without that item, core Ebitda excluding one-offs still grew 20% by our math.
What to watch: fourth-quarter core Ebitda excluding one-offs, which the full-year outlook puts at $690 million by our math. A drop to that level would take the core margin down from 65.3% in Q3 to 54.3%.
Operating Cash Doubled and Trimmed Net Debt
Cash generation accelerated in the third quarter because legal settlement payouts ended and operating profit rose. Bausch Health generated $813 million in cash from operating activities, up 101% from $405 million a year ago, as legacy legal payments dropped to zero from $87 million. Excluding one-offs and Bausch + Lomb, the core business produced $539 million of operating cash flow.
Appio said that cash generation supported "more than $500 million of net debt reduction during the quarter". Across the whole group, cash and equivalents rose to $2.49 billion from $1.83 billion in June, cutting consolidated net debt — total debt principal minus unrestricted cash — by $731 million from last quarter to $17.68 billion by our math. The company also raised its full-year core cash flow plan by $200 million.
What to watch: fourth-quarter core operating cash flow excluding one-offs, which the raised outlook implies at $308 million by our math. That step-down from $539 million tests how much cash the business retains when working capital normalizes.
🐻 Bear Case
Solta Underlying Sales Shrank Outside the China Deal
Solta Medical, the medical-aesthetics unit that makes Thermage skin-tightening devices, is supposed to be the growth engine that outlasts upcoming drug patent expirations. Last quarter, management highlighted vertical integration in China as a major profit driver after buying its local distributor in December 2025. In the third quarter, Solta's reported sales rose 18% to $165 million, "aided by the acquisition of our full service distributor in China".
However, that acquisition added $29 million of revenue that is excluded from like-for-like comparisons. Sales from businesses owned a year ago actually fell 4% to $134 million, "with the Asia Pacific region decreasing modestly", Bausch Health said. Underlying growth in Solta has slowed from 24% a year ago to 19% in Q1, 12% in Q2, and minus 4% now, showing that the reported jump is a one-time accounting step-up rather than expanding demand.
What to watch: Solta's segment profit in the third-quarter filing and underlying sales in Q1 2027, when the China deal laps. Another negative reading would show that aesthetics demand in Asia is contracting.
Debt Principal Exceeds $20 Billion as 2027 Approaches
Despite strong third-quarter cash flow, the company's debt load still towers over an earnings base that faces regulatory price cuts in two months. Total debt principal stood at $20.17 billion on September 30, down only $64 million from the end of 2025 because Bausch Health kept its cash on the balance sheet rather than retiring debt early. Net interest expense consumed $385 million in the quarter alone.
Meanwhile, negotiated Medicare prices for Xifaxan — the gut drug that drives Salix's $831 million of quarterly revenue — take effect in 2027, followed by expected generic competition and $3.77 billion of debt maturities in 2028. Even after raising its 2026 core Ebitda plan to $3.25 billion at the middle of the range, the release gave no update on 2027, leaving the debt wall aligned with the Xifaxan pricing reset.
What to watch: formal 2027 outlook figures when fourth-quarter results arrive in early 2027. A core Ebitda target near the previously discussed $2.7 billion mark would confirm a steep profit drop next year.
Risks this quarter didn't answer
Four standing risks from prior quarters depend on disclosures that live in the quarterly call or the full 10-Q filing rather than the earnings release.
- Xifaxan prescription volume vs price: the release states 16% revenue growth for Xifaxan, but retail prescriptions excluding Medicaid are only given on the call.
- Solta segment profit and net debt excluding Bausch + Lomb: segment profit tables and the exact split of the $20.17 billion debt load arrive in the 10-Q.
- Bausch + Lomb separation and Tampa factory inspection: the release repeats that management is evaluating options to unlock value, with no update on the FDA inspection status at Tampa.
- Xifaxan patent and antitrust lawsuits: litigation updates appear in the 10-Q legal footnotes.
👓 Other Themes
New $50M Share Buyback Offsets 2027 Stock Grants
After keeping buybacks off the table for over a year to focus on debt reduction, the board authorized a $50 million share repurchase programme. Bausch Health said the plan comes "with the primary objective of offsetting dilution associated with the anticipated vesting of management equity awards in 2027". Diluted share count rose 1.4% from a year ago to 380.7 million as employee stock grants vested.
Tariff Estimates Remain Inside the 2026 Plan
Bausch Health kept estimated tariff costs for calendar 2026 inside its raised full-year outlook. The pharmaceutical maker noted that rapid shifts in trade rules and retaliatory tariffs create uncertainty, and it continues to assess direct and indirect effects on its supply chain, where key drugs are made in Canada and Europe. Management warned it cannot guarantee that future trade measures will not hurt results.
💲 Other KPIs
Sales at the eye-health subsidiary rose 7% both as reported and from businesses owned a year ago, matching its 7% underlying pace across the first nine months of 2026. Pharmaceuticals grew 11% to $367 million and Surgical rose 8% on an underlying basis to $234 million. Segment Ebitda excluding one-offs rose 33% to $328 million.
Sales in the Diversified unit — which sells skin, nerve, dental and generic drugs — rose 5% from a year ago, reversing a 10% drop in Q1 and a 0% reading in Q2. A 28% underlying jump in Dermatology to $86 million and 1% growth in Neuroscience to $146 million offset a 28% underlying drop in Generics.
International pharmaceutical revenue grew 5% as reported and 4% from businesses owned a year ago, following 5% underlying growth in the second quarter and 0% in the first quarter. Currency shifts added $4 million to the top line, and the Canadian business led the underlying gain after shrinking 9% in the prior quarter.
🔮 Guidance
Raised. The middle of the full-year range moved up by $160 million to $11.075 billion, which represents 7.9% growth from 2025 by our math. By our math, that leaves $2.76 billion for the fourth quarter, a 1.4% drop from a year ago. This is the third raise this year, and each move has grown larger: +$45M, +$120M, +$160M.
Raised. The pharmaceutical group lifted the middle of its core revenue plan by $150 million to $5.575 billion, calling for 7% to 9% growth over 2025. By our math, that leaves $1.27 billion for Q4, down 8.6% from last year's fourth quarter due to year-end Medicare rebate accruals and Aplenzin generic competition. Prior moves this year were $0M, +$100M, and +$150M.
Raised. The eye-health subsidiary nudged the middle of its revenue target up by $10 million to $5.50 billion, or 7.8% growth for the year by our math. By our math, the outlook implies $1.49 billion of revenue in the fourth quarter, up 5.8% from a year ago. It is the third raise of 2026, with each step smaller than the last: +$45M, +$20M, +$10M.
Raised. Management lifted the middle of the consolidated Ebitda plan by $252.5 million to $4.365 billion after the third-quarter margin expansion. That marks the third raise in three quarters, with the increases accelerating across the year: +$10M in Q1, +$165M in Q2, and +$252.5M in Q3.
Raised. The core Ebitda target rose by $187.5 million at the middle of the range to $3.25 billion, or 12% to 14% growth for the year. By our math, that leaves $690 million for the fourth quarter, down from $1.02 billion in Q3 and implying a 54.3% Q4 margin. Moves across 2026 were $0M, +$150M, and +$187.5M.
Raised. Bausch + Lomb raised the middle of its full-year Ebitda outlook by $65 million to $1.115 billion. Across the first three quarters of 2026, the unit has delivered $763 million of Ebitda excluding one-offs, leaving $352 million for the fourth quarter by our math. The three raises this year were +$10M, +$15M, and +$65M.
Raised. The middle of the core operating cash flow plan rose by $200 million for a second straight quarter, reaching $1.638 billion. With $1.33 billion already collected in the first nine months of 2026 by our math, the outlook implies $308 million in the fourth quarter, down from $539 million in Q3.
❓ Key Questions
Did Xifaxan prescription volume grow in the third quarter?
Xifaxan revenue rose 16%, but the press release did not disclose retail prescriptions excluding Medicaid. Because prior growth relied on higher net prices after exiting government rebate channels, investors need the prescription count to see if patient demand is growing before 2027 price cuts.
Does the 2027 core Ebitda target stay at $2.7B?
Management raised the 2026 core Ebitda plan by $187.5 million to $3.25 billion, but the release said nothing about 2027. Last quarter, executives held the 2027 target at $2.7 billion, so an unchanged figure would mean a wider $550 million drop next year.
Why did Solta underlying sales shrink in Asia Pacific?
Solta Medical's sales from businesses owned a year ago fell 4%, reversing three quarters of double-digit gains. Management should explain whether the drop in Asia Pacific reflects weaker consumer spending in China and South Korea or order timing.
What was Solta's segment profit in the third quarter?
Last quarter, management projected a $330 million annual segment-profit pace for Solta after buying its Chinese distributor. The earnings release omits segment profit tables, so the 10-Q filing must show whether Solta held its margin while underlying revenue fell.